Tel: 01789 267520

Olesoxime (Trophos) Updates

Olesoxime is a neuro-protective drug that supports the nervous system under stressful conditions. In January 2015, a Phase II clinical trial with young people aged 3 – 25 with SMA Type 2 or 3, indicated that Olesoxime is safe, well tolerated, and able to positively impact disease progression. At the same time, Roche pharmaceutical company agreed to purchase the small, late-stage clinical drug testing company, Trophos that originally developed the drug.

Clinical Trials Now


Roche Community Update: Olesoxime


Roche to buy Trophos


Trophos Announces Positive Olesoxime Phase II Trial Results


Olesoxime, A Drug With Potential To Treat SMA, Passes Early Safety Testing

Recruitment For Phase Two Clinical Trial Now Fully Open

Announcement Of Phase Two Clinical Trial For SMA Patients